BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 17656562)

  • 1. Novel tubulin-targeting agents: anticancer activity and pharmacologic profile of epothilones and related analogues.
    Fumoleau P; Coudert B; Isambert N; Ferrant E
    Ann Oncol; 2007 Jul; 18 Suppl 5():v9-15. PubMed ID: 17656562
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epothilones as lead structures for new anticancer drugs--pharmacology, fermentation, and structure-activity-relationships.
    Altmann KH; Memmert K
    Prog Drug Res; 2008; 66():273, 275-334. PubMed ID: 18416309
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical investigations with epothilones in breast cancer models.
    Burris HA
    Semin Oncol; 2008 Apr; 35(2 Suppl 2):S15-21; quiz S39. PubMed ID: 18410795
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epothilones: a novel class of microtubule-stabilizing drugs for the treatment of cancer.
    Trivedi M; Budihardjo I; Loureiro K; Reid TR; Ma JD
    Future Oncol; 2008 Aug; 4(4):483-500. PubMed ID: 18684060
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epothilones: tubulin polymerization as a novel target for prostate cancer therapy.
    Lee JJ; Kelly WK
    Nat Clin Pract Oncol; 2009 Feb; 6(2):85-92. PubMed ID: 19048010
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The epothilones: how pharmacology relates to clinical utility.
    Michaud LB
    Ann Pharmacother; 2009 Jul; 43(7):1294-309. PubMed ID: 19584389
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting the microtubules in breast cancer beyond taxanes: the epothilones.
    Cortes J; Baselga J
    Oncologist; 2007 Mar; 12(3):271-80. PubMed ID: 17405891
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preclinical discovery of ixabepilone, a highly active antineoplastic agent.
    Lee FY; Borzilleri R; Fairchild CR; Kamath A; Smykla R; Kramer R; Vite G
    Cancer Chemother Pharmacol; 2008 Dec; 63(1):157-66. PubMed ID: 18347795
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potential clinical applications of epothilones: a review of phase II studies.
    Larkin JM; Kaye SB
    Ann Oncol; 2007 Jul; 18 Suppl 5():v28-34. PubMed ID: 17656559
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epothilones in prostate cancer: review of clinical experience.
    Dawson NA
    Ann Oncol; 2007 Jul; 18 Suppl 5():v22-7. PubMed ID: 17656558
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epothilones: clinical update and future directions.
    Donovan D; Vahdat LT
    Oncology (Williston Park); 2008 Apr; 22(4):408-16; discussion 416, 421, 424 passim. PubMed ID: 18472615
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of ixabepilone, a novel epothilone analogue.
    Pivot X; Dufresne A; Villanueva C
    Clin Breast Cancer; 2007 Apr; 7(7):543-9. PubMed ID: 17509162
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel microtubule-targeting agents - the epothilones.
    Cheng KL; Bradley T; Budman DR
    Biologics; 2008 Dec; 2(4):789-811. PubMed ID: 19707459
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epothilones in breast cancer: review of clinical experience.
    Fornier MN
    Ann Oncol; 2007 Jul; 18 Suppl 5():v16-21. PubMed ID: 17656557
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical experience with epothilones in patients with breast cancer.
    Buzdar AU
    Clin Breast Cancer; 2008 Mar; 8 Suppl 2():S71-8. PubMed ID: 18637402
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis & antitumor activity of epothilones B and D and their analogs.
    Cheng H; Huang G
    Future Med Chem; 2018 Jun; 10(12):1483-1496. PubMed ID: 29788770
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of other microtubule-stabilizer families: the epothilones and their derivatives.
    Brogdon CF; Lee FY; Canetta RM
    Anticancer Drugs; 2014 May; 25(5):599-609. PubMed ID: 24398663
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epothilones in the treatment of cancer.
    Larkin JM; Kaye SB
    Expert Opin Investig Drugs; 2006 Jun; 15(6):691-702. PubMed ID: 16732719
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacodynamics of tubulin and tubulin-binding agents: extending their potential beyond taxanes.
    Andreopoulou E; Muggia F
    Clin Breast Cancer; 2008 Mar; 8 Suppl 2():S54-60. PubMed ID: 18637400
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel drugs targeting microtubules: the role of epothilones.
    Ferrandina G; Mariani M; Andreoli M; Shahabi S; Scambia G; Ferlini C
    Curr Pharm Des; 2012; 18(19):2793-803. PubMed ID: 22390763
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.